Brainstorm Cell Therapeutics (BCLI) Stock Price, News & Analysis

Company Overview

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Key Stats

• Today's Range: $1.55 to $1.65
• 50-Day Range: $1.54 to $2.48
• 52-Week Range: $1.05 to $11.89
• Volume: 12,119 shs
• Average Volume: 63,861 shs
• Market Capitalization: $8.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $30.00
• Consensus Rating: Buy

Brainstorm Cell Therapeutics Stock Analysis - MarketRank™

Brainstorm Cell Therapeutics scored higher than 83% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Brainstorm Cell Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Brainstorm Cell Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Brainstorm Cell Therapeutics are expected to grow in the coming year, from ($3.01) to ($1.60) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Brainstorm Cell Therapeutics is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Brainstorm Cell Therapeutics is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.50% of the float of Brainstorm Cell Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Brainstorm Cell Therapeutics has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Brainstorm Cell Therapeutics has recently increased by 21.33%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Brainstorm Cell Therapeutics does not currently pay a dividend.

Dividend Growth

Brainstorm Cell Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.66

Percentage of Shares Shorted

2.50% of the float of Brainstorm Cell Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Brainstorm Cell Therapeutics has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Brainstorm Cell Therapeutics has recently increased by 21.33%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.22

News Sentiment

Brainstorm Cell Therapeutics has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Brainstorm Cell Therapeutics this week, compared to 1 article on an average week.

Search Interest

6 people have searched for BCLI on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

2 people have added Brainstorm Cell Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Brainstorm Cell Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.70% of the stock of Brainstorm Cell Therapeutics is held by insiders.

Percentage Held by Institutions

Only 14.33% of the stock of Brainstorm Cell Therapeutics is held by institutions.

BCLI Stock Analysis - Frequently Asked Questions

How have BCLI shares performed this year?

Brainstorm Cell Therapeutics' stock was trading at $2.27 on January 1st, 2025. Since then, BCLI shares have decreased by 31.3% and is now trading at $1.56.
View the best growth stocks for 2025 here.

How were Brainstorm Cell Therapeutics' earnings last quarter?

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) posted its quarterly earnings results on Wednesday, August, 14th. The biotechnology company reported ($0.60) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.60).

When did Brainstorm Cell Therapeutics' stock split?

Brainstorm Cell Therapeutics shares reverse split on Tuesday, October 1st 2024. The 1-15 reverse split was announced on Thursday, September 26th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Who are Brainstorm Cell Therapeutics' major shareholders?

Top institutional investors of Brainstorm Cell Therapeutics include Geode Capital Management LLC (0.92%), Liberty Wealth Management LLC (0.40%), Weaver Consulting Group (0.27%) and Two Sigma Securities LLC (0.20%). Insiders that own company stock include Chaim Lebovits, Stacy Lindborg and Ibrahim B Dagher.
View institutional ownership trends.

How do I buy shares of Brainstorm Cell Therapeutics?

Shares of BCLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Brainstorm Cell Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Brainstorm Cell Therapeutics investors own include Coca-Cola (KO), Organovo (ONVO), Gene Biotherapeutics (CRXM), Anavex Life Sciences (AVXL), Sangamo Therapeutics (SGMO), Protalix BioTherapeutics (PLX) and Isoray (ISR).

Company Calendar

• Last Earnings: 8/14/2024
• Today: 3/03/2025
• Next Earnings (Estimated): 4/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BCLI
• CIK: 1137883
• Web: www.brainstorm-cell.com
• Phone: (201) 488-0460
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $30.00
• High Stock Price Target: $30.00
• Low Stock Price Target: $30.00
• Potential Upside/Downside: +1,823.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($4.80)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-17,190,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -528.56%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.05
• Quick Ratio: 0.05

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.20) per share
• Price / Book: -1.30

Miscellaneous

• Outstanding Shares: 5,703,000
• Free Float: 5,321,000
• Market Cap: $8.90 million
• Optionable: Optionable
• Beta: 0.26